Previous 10 | Next 10 |
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the financial results for the period ended March 31, 2020. The webcast will begin at 6pm EDT Wednesday, Ma...
Key points: Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy, publishes three peer-reviewed articles detailing results from three separate trials of remestemcel-L in children and adults with acut...
Mesoblast (MESO) is an Australian company at the forefront of regenerative therapies with its lead product Remestemcel-L already approved for use in pediatric graft versus host disease ((GVHD)) in Japan marketed as TEMCELL by its partner JCR Pharmaceuticals (TYO:4552). Mesoblast has commerci...
Shares of Mesoblast (NASDAQ: MESO) rose as much as 27.2% today after the company announced the pricing of an offering of common stock. The stem cell developer will issue up to 43 million shares of common stock at AUD$3.20 apiece on the Australian Securities Exchange (ASX). The business expec...
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), a leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a capital raising of US$90 million¹ (A$138 million) via a private placement of 43 mi...
The SARS-CoV2 pandemic has ignited a massive effort across the globe, led by medical researchers and biotech companies, to come up with therapies that can help patients and bring an end to the pandemic. Vaccines, antibodies, immunity and convalescent plasma have all become common medical ter...
CPS Technologies (NASDAQ: CPSH ) +71% on Q1 results . More news on: CPS Technologies Corporation, Medigus Ltd., Predictive Oncology Inc., Stocks on the move, , Read more ...
Mesoblast Limited (NASDAQ: MESO ) is up 12% premarket on light volume in reaction to its announcement that the first participants have been dosed in a 300-subject Phase 2/3 clinical trial evaluating cell therapy remestemcel-L in COVID-19 patients with moderate-to-severe ...
NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the first patients have been dosed in the 300-patient randomized placebo-controlled Phase 2/3 trial in the United States o...
May 1, 2020 Palm Beach, FL – May 1, 2020 – America’s public-private sector collaboration on the global health crisis appears to have borne fruit… very quickly. The government has streamlined regulations and the public sector has responded with unheard o...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...